Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Aurinia Pharmaceuticals (AUPH)
NASDAQ:AUPH
RESEARCH TOOLSreports
Holding AUPH?
Track your performance easily
Earnings Data
Report Date
Mar 04, 2025TBA Not Confirmed
Period Ending
2024 (Q4)Consensus EPS Forecast
$0.02Last Year’s EPS
-$0.19Same Quarter Last Year
Strong Buy
Based on 4 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Nov 07, 2024
|% Change Since: 20.08%
|Next Earnings Date:Mar 04, 2025
Earnings Call Sentiment|Neutral
The earnings call highlighted strong revenue growth and strategic progress, including significant milestones in product approvals and R&D. However, the restructuring and substantial workforce reduction indicate underlying challenges in operational efficiency and cost management, balancing the positive aspects.Company Guidance
In the third quarter of 2024, Aurinia Pharmaceuticals demonstrated robust financial performance, reporting a total net revenue of $67.8 million, a 24% increase from $54.5 million in the same period of 2023. Year-to-date, total net revenue reached $175.3 million, marking a 34% growth compared to $130.4 million in 2023. Net product revenue for the quarter was $55.5 million, a 36% increase from $40.8 million in the prior year. The company also reported a cash flow from operations of $17 million and held $348.7 million in cash, cash equivalents, and investments as of September 30, 2024. The commercial success was reflected in the addition of 364 PSFs and 146 new patients, totaling 510, representing a 17% year-over-year growth. The total number of patients on LUPKYNIS therapy grew by 25% to approximately 2,422. Aurinia reiterated its net product revenue guidance range of $210 million to $220 million, underscoring confidence in its commercial strategy, despite announcing a workforce reduction of approximately 45% to achieve more than $40 million in annualized cash-based operating expense savings. The company also highlighted milestones, including the dosing of the first participant in a Phase I study of AUR200 and a $10 million milestone payment following Japanese regulatory approval of LUPKYNIS for lupus nephritis.Strong Revenue Growth
Total net revenue for Q3 2024 was $67.8 million, a 24% growth compared to $54.5 million in Q3 2023. For the first 9 months of 2024, total net revenue increased by 34% to $175.3 million from $130.4 million in the same period in 2023.
Increased Net Product Revenue
Net product revenue for Q3 2024 was $55.5 million, a 36% increase from $40.8 million in Q3 2023. For the first 9 months of 2024, net product revenue grew by 36% to $158.6 million compared to $116.2 million in the same period in 2023.
Japanese Approval Milestone
Japanese regulatory authorities approved LUPKYNIS to treat lupus nephritis, triggering a $10 million milestone payment and anticipating low double-digit royalties on net sales in Japan.
Cash Flow and Financial Position
The company generated $17 million in cash flow from operations in Q3 2024. Cash and investments were $348.7 million as of September 30, 2024, reflecting strong operational execution.
R&D Progress
The first participant was dosed in a Phase I study of AUR200, a BAFF/APRIL dual antagonist for autoimmune disorders, with results expected in 2025.
---
AUPH Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
AUPH Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Nov 07, 2024 | $7.52 | $8.34 | +10.90% |
| Aug 01, 2024 | $5.88 | $5.61 | -4.59% |
| May 02, 2024 | $5.20 | $5.17 | -0.58% |
| Feb 15, 2024 | $7.97 | $6.02 | -24.47% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Aurinia Pharmaceuticals (AUPH) report earnings?
Aurinia Pharmaceuticals (AUPH) is schdueled to report earning on Mar 04, 2025, TBA Not Confirmed.
What is Aurinia Pharmaceuticals (AUPH) earnings time?
Aurinia Pharmaceuticals (AUPH) earnings time is at Mar 04, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is AUPH EPS forecast?
AUPH EPS forecast for the fiscal quarter 2024 (Q4) is $0.02.
---
